Q3 2026 Earnings

Revenue

$106.2B+11.4% YoY

Gross Profit

$3.7B3.5% margin

Operating Income

$1.6B1.5% margin

Net Income

$1.2B1.1% margin

EPS (Diluted)

$9.59

QoQ Revenue Growth

+2.9%

Operating Cash Flow

$1.2B

Free Cash Flow

$1.1B

Stock-Based Comp.

Total Assets

$84.2B

Total Liabilities

$84.3B

Stockholders' Equity

-$1.3B

Cash & Equivalents

$3.0B

Metric	Current	Year Ago	Change
Revenue	$106.2B	$95.3B	+11.4%
Gross Profit	$3.7B	$3.2B	+14.4%
Operating Income	$1.6B	$1.3B	+25.8%
Net Income	$1.2B	$879M	+34.9%

North American Pharmaceutical Segment

$88.3B83%

Oncology And Multispecialty Segment

$13.0B12%

Medical-Surgical Solutions Segment

$3.0B3%

Prescription Technology Solutions Segment

$1.5B1%

Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment

$335M0%